Orphan status in the U.S. can confer clinical-trial tax credits, user-fee exemptions, and up to seven years of post-approval market exclusivity for rare-disease programs. As a deuterated form of ...
Trevi Therapeutics (TRVI) advances Haduvio for IPF cough/RCC; Phase 2 IPF data strong, but funding, safety & opioid-label ...
Baseimmune, a biotechnology company leveraging computational protein design to create next-generation immunotherapies, today ...
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients ...
The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic coughFirst pivotal ...
What is Idiopathic Pulmonary Fibrosis (IPF)? IPF is a chronic, progressive, lung disease characterized by disabling shortness of breath, declining exercise capacity and extensive formation of scar ...
Add Yahoo as a preferred source to see more of our stories on Google. German pharma Boehringer Ingelheim has obtained FDA approval for its disease-modifying therapy Boehringer Ingelheim’s Jascayd ...
IPF has an insidious onset. It often presents with persistent dry cough associated with worsening breathlessness and progressive decline in one's exercise capacity. Hemoptysis (coughing up blood) is ...
Wall Street is turning constructive on three clinical-stage biotechs simultaneously, each sitting at the edge of a binary catalyst. The analyst calls on uniQure (NASDAQ:QURE), Syndax Pharmaceuticals ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Prior to this trial, CS014 had positive outcomes in an ...
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the trial’s ...
What is idiopathic pulmonary fibrosis (IPF)? Idiopathic pulmonary fibrosis (IPF) is a debilitating and fatal lung disease that affects approximately 3 million people worldwide. Despite the condition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results